Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy
Open Access
- 1 January 2024
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 7, 0488
Abstract
Immune checkpoint therapy, such as programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blockade, has achieved remarkable results in treating various tumors. However, most cancer patients show a low response rate to PD-1/PD-L1 blockade, especially those with microsatellite stable/mismatch repair-proficient colorectal cancer subtypes, which indicates an urgent need for new approaches to augment the efficacy of PD-1/PD-L1 blockade. Cholesterol metabolism, which involves generating multifunctional metabolites and essential membrane components, is also instrumental in tumor development. In recent years, inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine proteinase that regulates cholesterol metabolism, has been demonstrated to be a method enhancing the antitumor effect of PD-1/PD-L1 blockade to some extent. Mechanistically, PCSK9 inhibition can maintain the recycling of major histocompatibility protein class I, promote low-density lipoprotein receptor-mediated T-cell receptor recycling and signaling, and modulate the tumor microenvironment (TME) by affecting the infiltration and exclusion of immune cells. These mechanisms increase the quantity and enhance the antineoplastic effect of cytotoxic T lymphocyte, the main functional immune cells involved in anti-PD-1/PD-L1 immunotherapy, in the TME. Therefore, combining PCSK9 inhibition therapy with anti-PD-1/PD-L1 immunotherapy may provide a novel option for improving antitumor effects and may constitute a promising research direction. This review concentrates on the relationship between PCSK9 and cholesterol metabolism, systematically discusses how PCSK9 inhibition potentiates PD-1/PD-L1 blockade for cancer treatment, and highlights the research directions in this field.Keywords
Funding Information
- National Natural Science Foundation of China (82202884)
This publication has 146 references indexed in Scilit:
- Molecular mechanisms of Sonic hedgehog mutant effects in holoprosencephalyProceedings of the National Academy of Sciences, 2005
- THE WNT SIGNALING PATHWAY IN DEVELOPMENT AND DISEASEAnnual Review of Cell and Developmental Biology, 2004
- Global Defects in the Expression and Function of the Low Density Lipoprotein Receptor (LDLR) Associated with Two Familial Hypercholesterolemia Mutations Resulting in Misfolding of the LDLR Epidermal Growth Factor-AB PairJournal of Biological Chemistry, 2004
- Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol AbsorptionScience, 2004
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences, 2003
- Ca2+ binding to complement-type repeat domains 5 and 6 from the low-density lipoprotein receptor-related proteinBMC Biochemistry, 2003
- Skinny Hedgehog, an Acyltransferase Required for Palmitoylation and Activity of the Hedgehog SignalScience, 2001
- The Hedgehog and Wnt signalling pathways in cancerNature, 2001
- Inhibition of Selenoprotein Synthesis by Selenocysteine tRNA[Ser]Sec Lacking IsopentenyladenosineJournal of Biological Chemistry, 2000